Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

101. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110) Full Text available with Trip Pro

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110) The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront use of fluoropyrimidine

2019 EvidenceUpdates

102. The role of the intestinal microbiome in the short- and long-term outcomes of colorectal cancer surgery: a systematic review

The role of the intestinal microbiome in the short- and long-term outcomes of colorectal cancer surgery: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

103. The prognostic significance of preoperative serum albumin in colorectal cancer: a systematic review and meta-analysis

The prognostic significance of preoperative serum albumin in colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

104. Non-genetic biomarkers and risk of colorectal cancer: an umbrella review of meta-analyses of observational studies, meta-analyses of randomised controlled trials and Mendelian randomisation studies

Non-genetic biomarkers and risk of colorectal cancer: an umbrella review of meta-analyses of observational studies, meta-analyses of randomised controlled trials and Mendelian randomisation studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

105. Is the enhanced recovery after surgery (ERAS) program effective and safe in laparoscopic colorectal cancer surgery? a meta-analysis of randomized controlled trials

Is the enhanced recovery after surgery (ERAS) program effective and safe in laparoscopic colorectal cancer surgery? a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

106. Faecal immunochemical test (FIT) to triage patients with lower abdominal symptoms suspected for colorectal cancer in primary care: review of international use and guidelines

Faecal immunochemical test (FIT) to triage patients with lower abdominal symptoms suspected for colorectal cancer in primary care: review of international use and guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

107. Breast and colorectal cancer awareness in Malaysians and barriers towards screening: a systematic review

Breast and colorectal cancer awareness in Malaysians and barriers towards screening: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

108. Primary tumour resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis

Primary tumour resection in patients with incurable localized or metastatic colorectal cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2019 PROSPERO

109. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis Full Text available with Trip Pro

Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis Patients with longstanding ulcerative colitis (UC) and colonic Crohn's disease (CD) have an increased risk of colorectal cancer (CRC). We assess the effectiveness of endoscopic surveillance in patients with inflammatory bowel disease (IBD) for diagnosing CRC and reducing CRC-related mortality.MEDLINE, EMBASE, and CENTRAL were searched from inception to 19 (...) on the degree of heterogeneity; pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel method.Five observational studies evaluating 7199 IBD patients were included; no RCTs met criteria for inclusion. There are limited new studies evaluating this clinical question (last included study published 2014). There was a significantly higher rate of cancer detection in the non-surveillance group (3.2%, 135/4256) compared to the surveillance group (1.8%, 53/2895

2018 EvidenceUpdates

110. Screening for Colorectal Cancer

Screening for Colorectal Cancer CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus Desmond Leddin, 1,2, * David A. Lieberman, 3, * Frances Tse, 4 Alan N. Barkun, 5 Ahmed M. Abou-Setta, 6 John K. Marshall, 4 N. Jewel Samadder, 7 Harminder Singh, 6,8 Jennifer J. Telford, 9 Jill Tinmouth, 10 Anna N. Wilkinson, 11 (...) Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada BACKGROUND & AIMS: A family history (FH) of colorectal cancer (CRC) increases the risk of developing CRC. These consensus recommendations developed by the Canadian As- sociation of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on screening these high-risk individuals. METHODS: Multiple parallel systematic review streams, informed by 10 literature searches, assembled

2018 Canadian Association of Gastroenterology

111. Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. Full Text available with Trip Pro

Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. For patients with asymptomatic, incurable, metastatic colorectal cancer, palliative, systemic treatment can be started immediately, or can be delayed until disease-related symptoms occur. How the potential survival benefit of starting palliative, systemic treatment immediately after diagnosis weighs up against the potential side effects is currently under debate (...) August 2018. We did not apply limitations based on language or date of publication. We searched the reference lists of all included studies to identify trials that may not have been identified from the electronic searches.Randomised controlled trials evaluating immediate versus delayed chemotherapy in persons with asymptomatic, metastatic, incurable colorectal cancer.We applied standard methodological procedures, according to the recommendations of Cochrane and Cochrane Colorectal Cancer. Two review

2018 Cochrane

112. Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC)

Bevacizumab (Mvasi) - Metastatic Colorectal Cancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product

2018 Health Canada - Drug and Health Product Register

113. Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342)

Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome (CAT#3342) UTCAT3342, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental radiograph as an opportunistic screening tool for a colorectal cancer syndrome Clinical Question Does dental radiograph serve as an opportunistic screening tool for early detection of extraintestinal manifestations of Familial Adenomatous Polyposis (FAP (...) ) in children and adults? Clinical Bottom Line Incidental findings on dental radiographs could serve as screening tools for systemic diseases and syndromes. The attention should be raised when gene mutation, congenitally diseases or familial colorectal cancer are reported by patients during the medical history questionnaire. For patients with risk of FAP, the Dental panoramic radiographic score (DPRS) is inexpensive, and reinforce the referral for the further clinical investigation, gene mapping

2018 UTHSCSA Dental School CAT Library

114. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial Full Text available with Trip Pro

Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has

2018 EvidenceUpdates

115. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis Colorectal cancer screening (CRC) is recommended by all major US medical organizations but remains underused.To identify interventions associated with increasing CRC screening rates and their effect sizes.PubMed, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and ClinicalTrials.gov were searched from January 1, 1996 (...) , to August 31, 2017. Key search terms included colorectal cancer and screening.Randomized clinical trials of US-based interventions in clinical settings designed to improve CRC screening test completion in average-risk adults.At least 2 investigators independently extracted data and appraised each study's risk of bias. Where sufficient data were available, random-effects meta-analysis was used to obtain either a pooled risk ratio (RR) or risk difference (RD) for screening completion for each type

2018 EvidenceUpdates

116. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review Full Text available with Trip Pro

Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review Despite clear evidence that colorectal cancer (CRC) screening reduces mortality, screening, including fecal immunochemical tests (FIT), is underutilized. We conducted a systematic review to determine the evidence of efficacy of interventions to improve FIT completion that could be scaled and utilized in population health management. We systematically searched publication

2018 EvidenceUpdates

117. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study. Full Text available with Trip Pro

Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study. The fecal immunochemical test (FIT) is commonly used for colorectal cancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex.To identify programmatic (multitest) FIT performance characteristics and optimal FIT quantitative hemoglobin positivity (...) thresholds in a large, population-based, screening program.Retrospective cohort study.Kaiser Permanente Northern and Southern California.Adults aged 50 to 75 years who were eligible for screening and had baseline quantitative FIT results (2013 to 2014) and 2 years of follow-up. Nearly two thirds (411 241) had FIT screening in the previous 2 years.FIT programmatic sensitivity for CRC and number of positive test results per cancer case detected, overall and by age and sex.Of 640 859 persons who completed

2018 Annals of Internal Medicine

118. Recent advances in colorectal cancer screening Full Text available with Trip Pro

Recent advances in colorectal cancer screening 30276360 2018 11 14 2589-0514 4 3 2018 Sep Chronic diseases and translational medicine Chronic Dis Transl Med Recent advances in colorectal cancer screening. 139-147 10.1016/j.cdtm.2018.08.004 Li Dan D Department of Gastroenterology, Kaiser Permanente Medical Center, Santa Clara, CA 95051, USA. Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA. eng Editorial 2018 09 17 China Chronic Dis Transl Med 101679934 2095 (...) -882X Colonoscopy Colorectal cancer Screening 2018 06 26 2018 10 3 6 0 2018 10 3 6 0 2018 10 3 6 1 epublish 30276360 10.1016/j.cdtm.2018.08.004 S2095-882X(18)30060-4 PMC6160607 Lancet. 2013 Apr 6;381(9873):1185-93 23414648 Am J Surg Pathol. 2004 Nov;28(11):1452-9 15489648 Gastroenterology. 2016 Nov;151(5):870-878.e3 27443823 CA Cancer J Clin. 2017 May 6;67(3):177-193 28248415 Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7 26226577 Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330

2018 Chronic diseases and translational medicine

119. Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial Full Text available with Trip Pro

Effectiveness of a Mailed Colorectal Cancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial Approximately 24 million US individuals receive care at federally qualified health centers, which historically have low rates of colorectal cancer screening. The US Preventive Services Task Force recommends routine colorectal cancer screening for individuals aged 50 to 75 years.To determine the effectiveness of an electronic health record (EHR (...) )-embedded mailed fecal immunochemical test (FIT) outreach program implemented in health centers as part of standard care.This cluster randomized pragmatic clinical trial was conducted in 26 federally qualified health center clinics, representing 8 health centers in Oregon and California, randomized to intervention (n = 13) or usual care (n = 13). All participants were overdue for colorectal cancer screening during the accrual interval (February 4, 2014 to February 3, 2015).Electronic health record

2018 EvidenceUpdates

120. Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer Full Text available with Trip Pro

Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer 30225389 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer. 55 10.21037/tgh.2018.07.11 Abdel-Rahman Omar O Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Department of Oncology, University of Calgary, Tom Baker Cancer Centre (...) Cancer. 2013 Sep 15;119(18):3377-84 23801109 Clin Transl Oncol. 2018 Jun;20(6):794-800 29086248 Cancer. 2018 Jul 15;124(14):3008-3015 29797673 J Gastrointest Cancer. 2013 Jun;44(2):203-10 23264206 Gastrointest Cancer Res. 2007 Nov;1(6):248-53 19262903 J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):664-672 29766660 Clin Colorectal Cancer. 2016 Mar;15(1):16-23 26281943 Ann Oncol. 2013 Oct;24 Suppl 6:vi64-72 24078664 J Nutr. 1994 Jun;124(6):906-10 7515956 J Cancer Surviv. 2012 Dec;6(4):398-406 23054848 Dig

2018 Translational gastroenterology and hepatology